Therapeutic Properties And Pharmacological Activities Of Asiaticoside And Madecassoside: A Review Part 2
Jun 08, 2023
4. OTHER ORGAN-PROTEC TIVE EFFEC TS OF ASIATICOSIDE AND MADECASSOSIDE
4.1 Hepatoprotective properties
Intararuchikul, Thidarat, et al. identified that supplementation of the standardized extract of C. asiatica (ECa233) protects rat liver against rotenone toxicity (a natural pesticide), and ECa233 administration before rotenone exposure inhibits lipid peroxidation in liver tissue and also enhances the expression of catalase endogenous antioxidant enzyme. This hepatoprotective activity can be attributed to the antioxidant properties of the constituent triterpenoids in the herb.103
Glycoside of cistanche can also increase the activity of SOD in heart and liver tissues, and significantly reduce the content of lipofuscin and MDA in each tissue, effectively scavenging various reactive oxygen radicals (OH-, H₂O₂, etc.) and protecting against DNA damage caused by OH-radicals. Cistanche phenylethanoid glycosides have a strong scavenging ability of free radicals, a higher reducing ability than vitamin C, improve the activity of SOD in sperm suspension, reduce the content of MDA, and have a certain protective effect on sperm membrane function. Cistanche polysaccharides can enhance the activity of SOD and GSH-Px in erythrocytes and lung tissues of experimentally senescent mice caused by D-galactose, as well as reduce the content of MDA and collagen in lung and plasma, and increase the content of elastin, have a good scavenging effect on DPPH, prolong the time of hypoxia in senescent mice, improve the activity of SOD in serum, and delay the physiological degeneration of lung in experimentally senescent mice With cellular morphological degeneration, experiments have shown that Cistanche has the good antioxidant ability and has the potential to be a drug to prevent and treat skin aging diseases. At the same time, echinacoside in Cistanche has a significant ability to scavenge DPPH free radicals and can scavenge reactive oxygen species, prevent free radical-induced collagen degradation, and also has a good repair effect on thymine free radical anion damage.

Click On Antioxidants Cistanche For Sale
【For more info: david.deng@wecistanche.com / WhatApp:86 13632399501】
An earlier study was carried out on the effect of asiaticoside, madecassoside, and Asiatic acid on cyclophosphamide (CYP)-induced hepatotoxicity and immunosuppression in rats. Upon administration of the triterpene saponins, the relative weights of immune organs were restored to normal in the CYP-treated rats, the production of inflammatory cytokines was suppressed, and the previously low levels of antioxidants were restored. Overall, the saponins can protect against hepatic damage against immune-mediated liver disease and also prevent multiorgan injury.104
Asiaticoside and madecassoside have shown significant protection against lipopolysaccharide (LPS)/D-galactosamine (D-GaIN)- induced acute liver injury in two separate studies. Asiaticoside presented anti-inflammatory effects and dose-dependently reduced elevated aminotransferases, hepatocytes apoptosis, and caspase-3, as well as improved mortality and liver pathological injury. Furthermore, asiaticoside inhibited the expression of TNF-alpha and MAPKs to protect against hepatic damage.105 Madecassoside exhibited both antioxidative and anti-inflammatory effects in LPS/D-GalN-induced hepatic damage in mice. Madecassoside attenuated liver injury by protecting liver function, suppressing the production of inflammatory cytokines (TNF-α, IL-1β, and IL-6), restoring/enhancing antioxidant enzyme activity, and suppressing LPS-stimulated proteins.106 Thus asiaticoside and madecassoside are promising hepatoprotective agents for acute liver injury or liver failure.
Drug-induced liver injury and acute liver failure (ALF) are often caused by accidental overdose and adverse side effects of the drug N-acetyl-p-aminophenol (acetaminophen, APAP) which is a popular analgesic and antipyretic agent; excessive APAP results in oxidative stress in liver tissues due to increase in MDA content and reduction in GSH levels, as well as inflammatory cell infiltration and overexpression of pro-inflammatory cytokines (such as TNF-α and IL-1β), ultimately leading to hepatoxicity. The observed GSH depletion, MDA overproduction, and overexpressed inflammatory markers caused by APAP have been seen to be reversed by CA-HE50 treatment. The antioxidant and anti-inflammatory actions were identified to be due to the asiaticoside content present in the extract. Hence, asiaticoside is an effective phytochemical in protecting against APAP-induced liver injury.107
4.2 Pulmonary-protective properties
Pulmonary arteries have thinner walls and less vascular smooth muscles than systemic circulation, and one of the factors controlling pulmonary blood flow between the lungs and other organs is the vascular structure. Low oxygenation or hypoxia in tissues causes pulmonary vasoconstriction and if it persists long-term, the contraction is followed by remodeling of the vasculature, resulting in pulmonary hypertension.108 Pulmonary hypertension is associated with chronic lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchopulmonary dysplasia and is linked with reduced functioning and poor patient outcomes.109 Asiaticoside has been found to play a significant role in ameliorating hypoxia-induced pulmonary hypertension (PH).
Wang, Xiaobing, et al. demonstrated in an earlier study that asiaticoside can attenuate the development of PH in hypoxia-induced PH rat models by attenuating pulmonary cardiovascular remodeling and preventing right ventricular hypertrophy. These results were concluded to be most likely mediated by the action of asiaticoside in blocking the hypoxia-induced overactivity of the transforming growth factor (TGF)-β1/SMAD family member (SMAD) 2/3 signaling pathway as well as inhibiting the aberrant proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) which is a hallmark of vascular remodeling, by inducing their apoptosis.110 Research indicates that abnormal endothelial cells (ECs) apoptosis and ECs dysfunction is involved in the initiation and progression of PH. The same team conducted another study recently to further explore the effects of asiaticoside on hypoxic pulmonary hypertension in rats and human pulmonary artery endothelial cells (HPAECs) but with a special focus on the influence on endothelial cell function. Hypoxia interferes with NO production causing irregular morphology and dysfunction of endothelial cells experiencing PH; asiaticoside can activate nitric oxide (NO) production by enhancing the phosphorylation of serine/threonine-specific protein kinase/ eNOS, thus preventing ECs from hypoxic PH-induced apoptosis. Asiaticoside was also found to restore misadjusted levels of vascular mediators, preserve EC morphology and function, and protect against EC cell injury. In addition, asiaticoside was confirmed to regulate the PI3K/Akt signaling pathway both in vivo and in vitro to promote cell survival and viability.111

Asiaticoside also protects against lipopolysaccharide (LPS)- induced acute lung injury (ALI); the major feature of ALI is uncontrolled inflammatory responses in the lung and the NF-κB pathway is linked to the cytokines production and regulation of inflammatory responses.112 Asiaticoside has been studied to dose-dependently reduce LPS-induced pulmonary inflammation by inhibiting inflammatory infiltration, histopathological changes, cytokine production, and LPS-induced pulmonary edema via down-regulation of the NF-κB signaling pathway.113 Similarly, madecassoside exerts antiinflammatory action by downregulating the TLR4/NF-κB signaling pathway in LPS-induced acute lung injury and also protects the lungs by repairing LPS-induced pathological damages, lung edema, and alveolar epithelium integrity.114 Another serious lung disease is idiopathic pulmonary fibrosis (IPF) which is a chronic, progressive interstitial lung disease characterized by the aberrant proliferation of fibroblasts, excessive extracellular matrix (ECM), and chronic inflammation with poor prognosis; asiaticoside is known to attenuate bleomycin-induced pulmonary fibrosis by activating cAMP and Rap1 signaling pathways, thus inhibiting inflammation and fibrosis in the lungs.115 Madecassoside can also treat bleomycin-induced pulmonary fibrosis by preventing the deposition of extracellular matrix, achieved mainly through attenuating inflammation and oxidative stress in the early stages of pulmonary fibrosis as well as repressing collagen overproduction.116
Bronchopulmonary dysplasia (BPD) is another common pulmonary disease seen in premature infants with no effective therapy. BPD-associated pathological changes can cause hyperoxia-induced lung injury (HILI) in immature lung tissue, which can be markedly attenuated by asiaticoside via anti-inflammation and anti-apoptosis pathways in vitro and in vivo.117
4.3 Nephroprotective properties
Asiaticoside and madecassoside offer protection against renal diseases as well. Kidney inflammation initiates renal fibrosis, which results in progressive renal dysfunction and leads to chronic kidney disease (CKD) and eventually end-stage renal disease.118 Asiaticoside protects against renal fibrosis in vitro and in vivo as observed in a recent study.119 Asiaticoside also has a therapeutic role against nephropathy; nephropathy is a microvascular complication of diabetes mellitus that often leads to terminal renal failure and is generally characterized by structural and functional abnormalities in podocytes including podocyte hypertrophy, effacement, and apoptosis.120 Nephropathy can be inhibited by preventing podocyte injury and by ameliorating proteinuria. Asiaticoside treatment can mitigate the kidney histological damages induced by nephropathy. Furthermore, asiaticoside is seen to reduce urine protein excretion (proteinuria) in adriamycin-induced nephropathy rats. Asiaticoside is also observed to increase the expression of synaptopodin and decrease desmin expression in rat models, which restores the expression of cytoskeletal proteins in damaged podocytes and subsequently restores normal renal morphology. Asiaticoside also helps repair the glomerular filtration barrier of the kidneys which gets compromised in nephropathic progression.121 In another study using a C. asiatica extract, one of the major components was asiaticoside and it demonstrated several pharmacological effects in diabetic rats such as restoring the activities of kidney enzymes involved in glucose and amino acid oxidation in diabetes and protecting diabetic tissues from stress via antioxidant mechanisms to protect against diabetic kidney disease.122 Asiaticoside is the major constituent of the formula Compound Centella, which has proved effective in lowering the urine protein/ creatinine ratio in diabetic rats and can improve the renal pathology of diabetic kidney disease by regulating oxidative stress signaling.123 Madecassoside exhibits nephroprotective properties by protecting against nephrotoxicity; the chemotherapeutic drug doxorubicin (DOX) results in multi-organ injury including nephrotoxicity, during which it induces the apoptosis of Human Proximal Tubule Cells HK-2 cells. This DOX-induced cytotoxicity can be suppressed by treating with madecassoside, as it inhibits DOX-associated apoptosis and inflammation in HK-2 cells and can be considered for optimizing the DOX chemotherapeutic approach.124
5. MISCELLANEOUS ACTIVITIES
Asiaticoside and madecassoside offer numerous other medicinal benefits in treating cardiac, pancreatic, and colon diseases. Various extracts and compounds isolated from C. asiatica are seen to lower the occurrence of cardiovascular diseases such as cardiac hypertrophy, myocardial ischemia, atherosclerosis, and hypertension.125 Asiaticoside is reported to protect cardiomyocytes against myocardial oxygen–glucose deprivation/reoxygenation (OGD/R) injury.126 Madecassoside has a protective effect on isolated rat hearts and isolated cardiomyocytes against reperfusion injury in vitro, as well as in vivo; it is seen to protect rat models against myocardial ischemia–reperfusion injury-induced infarction through its anti-inflammatory, anti-oxidative and anti-apoptosis properties.127
Acute pancreatitis is characterized by tissue necrosis. Asiaticoside is proven to protect against mild acute pancreatitis (MAP) in caerulein-induced MAP models by inhibiting pancreatic acinar cells necrosis, ameliorating pancreatitis-associated histopathological changes, and lowering the severity of pancreatic tissue injury as well as pancreatitis-associated lung injury in a severe acute pancreatitis model.128 Madecassoside improves insulin sensitivity in pancreatic cells to promote glucose-stimulated insulin secretion (GSIS) and to enhance expression of insulin signaling proteins without any cytotoxic effects, making it a favorable drug compound in targeting type 2 diabetes mellitus.129
5.1 Anti-inflammatory, anti-allergic, and other immunomodulatory properties
A majority of the medicinal activity of asiaticoside and madecassoside can be attributed to their regulation of inflammatory immune responses. As mentioned previously, C. asiatica shows significant immunosuppressive action in the context of atopic dermatitis, where it suppresses the infiltration of immune cells and controls inflammation.82 Asiaticoside exhibits anti-inflammatory activity in regulating numerous diseases. According to Fong et al., asiaticoside might be a potential therapeutic agent for edema prevention in inflammatory diseases like atherosclerosis because it can prevent endothelial barrier dysfunction elicited by the pro-atherogenic cytokine, TNF-α. 130 Asiaticoside also shows protective effects against sepsis-induced acute kidney injury by inhibiting inflammation.131

One of the best pieces of evidence for the anti-inflammatory activity of these phytocompounds, particularly madecassoside, is protection against arthritis. Madecassoside shows further anti-inflammation effects in monosodium urate (MSU)-stimulated gouty arthritis and peritonitis. Gout is an inflammatory joint disease induced by MSU crystals accumulation, which is accompanied by the infiltration of neutrophils into joint spaces. Continued accumulation can lead to irreversible damage of the joint tissues and increases the risk of chronic inflammation.132 In a study by Lu et al., madecassoside suppressed MSU-induced inflammation in mice with gouty arthritis, alleviated neutrophil infiltration, and inhibited the secretion of proinflammatory mediators in mice with peritoneal inflammation.133 Similar anti-inflammatory benefits of madecassoside have been observed in mice with collagen-induced arthritis; Li et al. demonstrated that the madecassoside-treated arthritic mice showed improvement in the pathological damage to joint tissues, significant suppression of the pro-inflammatory molecules COX-2, PGE (2), TNF-alpha and IL- 6, as well as upregulation of the anti-inflammatory mediator IL-10.134 Madecassoside, is also seen to prevent the invasion of rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis by suppressing the NF-κB pathway-mediated inflammation.135 Furthermore, multiple studies verify the role of orally administered madecassoside in protecting against arthritis by similar action of inhibiting pro-inflammatory cytokines and upregulating anti-inflammatory ones.136–138 In a recent study, asiaticoside has been tested as an anti-inflammatory and immunomodulatory agent during in vivo implantation of polylactic-glycolic acid fibrous scaffolds. Electro-spun PLGA fibrous scaffolds are currently being tested in tissue engineering for bone, cartilage, skin, and neural regeneration, as well as for drug delivery systems; however, the accumulation of degradation products due to implantation causes host inflammatory response triggered by the innate immune cells (dendritic cells, mast cells, granulocytes, and macrophages) which hinders tissue regeneration. Based on varying microenvironments, macrophages can be polarized to form different phenotypes (M1 or M2) with different functions; the reversibility of polarization has critical therapeutic value, especially in diseases in which M1/M2 imbalance plays a pathogenic role. Asiaticoside can successfully suppress the expression of M1 (inflammatory) macrophages and inhibit the production of pro-inflammatory cytokines, while simultaneously promoting the expression of M2 macrophages, which consistently release anti-inflammatory cytokines. This is crucial in blocking host inflammatory response and achieving desirable implantation results, and asiaticoside is a favorable option for an anti-inflammatory drug.139,140
Asiaticoside also shows antiallergic properties. Mast cells which are associated with allergic inflammation, are immune cells that express a wide variety of membrane receptors involved in both innate and acquired immune responses. The main receptors are FcεRI, Toll-like receptors, complement receptors, and IgG receptors, which are involved in the activation of mast cells. Mast cells play a major role in the response to infections and are the main effectors in mediating response to allergens by degranulation and the release of histamine, pro-inflammatory cytokines, chemokines, and other vasoactive mediators.141 Asiaticoside can suppress allergic inflammation by blocking histamine release and mitigating mast cell degranulation, as well as reducing the generation of antigen-induced inflammatory factors, via the FcεRI-dependent signaling pathways.142
Furthermore, asiaticoside acts as an anti-inflammatory and antipyretic agent that has been studied to dose-dependently suppress lipopolysaccharide (LPS)-induced fever and inflammation in rats, presumably by the inhibition of pro-inflammatory mediators (serum tumor necrosis factor (TNF)-α, interleukin (IL)-6, liver myeloperoxidase (MPO), brain cyclooxygenase-2 (COX-2)) and the upregulation of liver heme oxygenase-1 (HO-1) protein activity (critical in preventing vascular inflammation.)143,144 Taking the abundant evidence of anti-inflammatory properties of asiaticoside as well as its regulation of macrophage polarization, mast cell degranulation and fever associated cytokines, more future studies dedicated to the effects of this natural extract on other immune responses may be beneficial from a clinical perspective.
5.2 Antipathogenic activities
Centella asiatica extracts can be considered a favorable option for natural anti-virulence drugs that can target the virulence of pathogens while maintaining their cell viability, which can help prevent the development of pathogenic resistance to antibiotics. The Centella triterpenoids can be considered phytoanticipins against a wide range of bacterial, fungal, and parasitic agents due to their antimicrobial activities, selective cytotoxicity, and protective function against pathogenic infections.3,145,146
An in vitro study by Vasanth et al. illustrates the effect of asiaticoside in reducing the production of cholera toxins in different strains of Vibrio cholera, showing promising biocidal activity that can be incorporated into revised treatments for cholera.10 Oral administration of asiaticoside has proved effective in treating the parasitic infection of visceral leishmaniasis caused by Leishmania donovani in infected mice models. Asiaticoside cleared almost all parasitic burdens in the liver and spleen as well as mediated a switch in the host from a Th2- to a Th1-type immune response, accompanied by induction of TNF-α-mediated nitric oxide production, which are important factors involved in macrophage function in antileishmanial defense mechanisms.38 Little evidence exists for the anti-viral effects of asiaticoside or madecassoside extracted from C. asiatica; however, asiaticoside derived from Hydrocotyle sibthorpioides (Apiaceae) is observed to significantly reduce the viral DNA transcription and replication of Hepatitis B virus (HBV) without resulting in toxicity.147
6. CONCLUSION
A variety of C. asiatica extracts have been extensively used in traditional medicine due to the wide spectrum of pharmacological activities associated with these secondary metabolites. This review highlights the activities of asiaticoside and madecassoside, the major saponin constituents of C. asiatica extracts, and provides a comprehensive view of their range of properties that can be harnessed for improving human health. Due to the lack of any reported adverse effects of C. asiatica in any clinical studies so far, the plant is categorized as a Class 1 herb (one that can safely be consumed when used appropriately) in the Botanical Safety Handbook. As illustrated in this review, research from the past two decades indicates a significant potential role for asiaticoside and madecassoside to be incorporated into modern treatment strategies, specifically targeting neurological and dermatological diseases, as well as offer potent benefits to a host of other medicinal and cosmetic requirements. Further research and clinical studies conducted on these compounds can offer novel therapeutic options and enhance existing medical knowledge through naturally occurring sources.

AUTHOR CONTRIBUTIONS
Shinjini Bandopadhyay: Conceptualization (supporting); investigation (equal); methodology (equal); writing – original draft (equal). Sujata Mandal: Formal analysis (supporting); writing – review and editing (supporting). Mimosa Ghorai: Data curation (supporting); writing – review and editing (supporting). Niraj Kumar Jha: Formal analysis (supporting); writing – review and editing (supporting). Manoj Kumar: Validation (supporting); writing – review and editing (supporting). Radha: Data curation (supporting); writing – review and editing (supporting). Arabinda Ghosh: Writing – review and editing (supporting). Jarosław Proćków: project administration (supporting); resources (supporting); supervision (supporting); validation (supporting); visualization (supporting); writing – review and editing (supporting). José M. Pérez de la Lastra: Funding acquisition (lead); methodology (equal); writing – review and editing (equal). Abhijit Dey: Conceptualization (lead); project administration (supporting); resources (supporting); supervision (lead); writing – review and editing (supporting).
FUNDING INFORMATION
This research was funded by project APOGEO (Cooperation Program INTERREG-MAC 2014-2020, with European Funds for Regional Development-FEDER, “Agencia Canaria de Investigación, Innovación y Sociedad de la Información (ACIISI) del Gobierno de Canarias”, project ProID2020010134, Caja Canarias, Project 2019SP43, and the State Plan for Scientific, Technical Research and Innovation 2021- 2023 from the Spanish Ministry of Science and Innovation (project PLEC2022-009507).
CONFLICT OF INTEREST
The authors declare no competing financial interests.
DATA AVAILABILITY STATEMENT
Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.
REFERENCES
1. Gray NE, Alcazar Magana A, Lak P, et al. Centella Asiatica – phyto chemistry and mechanisms of neuroprotection and cognitive enhancement. Phytochem Rev. 2018;17(1):161-194.
2. Brinkhaus B, Lindner M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medical plant Centella Asiatica. Phytomedicine. 2000;7(5):427-448.
3. James JT, Dubery IA. Pentacyclic triterpenoids from the medicinal herb, Centella asiatica (L.) urban. Molecules. 2009;14(10):3922- 3941.
4. James J, Dubery I. Identification and quantification of triterpenoid Centelloids in Centella asiatica (L.) urban by densitometric TLC. J Planar Chromat. 2011;24:82-87.
5. Hashim P, Sidek H, Helan MH, Sabery A, Palanisamy UD, Ilham M. Triterpene composition and bioactivities of Centella asiatica. Molecules. 2011;16(2):1310-1322.
6. Arora R, Kumar R, Agarwal A, Reeta KH, Gupta YK. Comparison of three different extracts of Centella Asiatica for anti-amnesic, antioxidant, and anticholinergic activities: in vitro and in vivo study. Biomed Pharmacother. 2018;105:1344-1352.
7. Shukla SD, Bhatnagar M, Khurana S. Critical evaluation of ayurvedadic plants for stimulating intrinsic antioxidant response. Front Neurosci. 2012;6:112.
8. Sun B, Wu L, Wu Y, et al. Therapeutic potential of Centella Asiatica and its triterpenes: a review. Front Pharmacol. 2020;11:568032.
9. Dahanukar S, Kulkarni R, Rege N. Pharmacology of medicinal plants and natural products. Indian J Pharmacol. 2000;32:81-118.
10. Vasanth S, Mohanraj RS, Mandal J. In-vitro study of the effect of Centella asiatica on cholera toxin production and the gene expression level of ctxA gene in Vibrio cholerae isolates. J Ethnopharmacol. 2021;279:113930.
11. Gohil KJ, Patel JA, Gajjar AK. Pharmacological review on Centella Asiatica: a potential herbal cure-all. Indian J Pharm Sci. 2010;72(5):546-556.
12. Hossain S, Urbi Z, Karuniawati H, et al. Andrographis paniculata (Burm. f.) wall. Ex Nees: an updated review of phytochemistry, antimicrobial pharmacology, and clinical safety and efficacy. Life (Basel). 2021;11(4):348.
13. Fahad FI, Barua N, Islam MS, et al. Investigation of the pharmacological properties of Lepidagathis hyaline Nees through experimental approaches. Life (Basel). 2021;11(3):180.
14. Bari MS, Khandokar L, Haque E, et al. Ethnomedicinal uses, phytochemistry, and biological activities of plants of the genus Gynura. J Ethnopharmacol. 2021;271:113834.
15. Moni JNR, Adnan M, Tareq AM, et al. Therapeutic potentials of Syzygium fruticosum fruit (seed) are reflected in an Array of pharmacological assays and prospective receptor-mediated pathways. Life (Basel). 2021;11(2):155.
16. Bristy TA, Barua N, Montakim Tareq A, et al. Deciphering the pharmacological properties of methanol extract of Psychotria calocarpa leaves by in vivo, in vitro, and in silico approaches. Pharmaceuticals (Basel). 2020;13(8):183.
17. Sinan KI, Akpulat U, Aldahish AA, et al. LC-MS/HRMS analysis, anti-cancer, anti-enzymatic and anti-oxidant effects of Boerhavia diffusa extract: a potential raw material for functional applications. Antioxidants (Basel). 2021;10(12):2003.
18. Shovo MARB, Tona MR, Mouah J, et al. Computational and pharmacological studies on the antioxidant, thrombolytic, anti-inflammatory, and analgesic activity of Molineria capitulate. Curr Issues Mol Biol. 2021;43(2):434-456.
19. Freitas MA, Vasconcelos A, Gonçalves ECD, et al. Involvement of opioid system and TRPM8/TRPA1 channels in the Antinociceptive effect of Spirulina platensis. Biomolecules. 2021;11(4):592.
20. Uddin Chy MN, Adnan M, Chowdhury MR, et al. Central and peripheral pain intervention by Ophiorrhizarugosa leaves: potential underlying mechanisms and insight into the role of pain modulators. J Ethnopharmacol. 2021;276:114182.
21. Ahmed S, Khan H, Aschner M, Mirzae H, Küpeli Akkol E, Capasso R. Anticancer potential of furanocoumarins: mechanistic and therapeutic aspects. Int J Mol Sci. 2020;21(16):5622.
22. Küpeli Akkol E, Genç Y, Karpuz B, Sobarzo-Sánchez E, Capasso R. Coumarins and Coumarin-related compounds in the pharmacotherapy of cancer. Cancers (Basel). 2020;12(7):1959.
23. Fernández J, Silván B, Entrialgo-Cadierno R, et al. The antiproliferative and palliative activity of flavonoids in colorectal cancer. Biomed Pharmacother. 2021;143:112241.
24. Ağagündüz D, Şahin TÖ, Yılmaz B, Ekenci KD, Şehriban DÖ, Capasso R. Cruciferous vegetables, and their bioactive metabolites: from prevention to novel therapies of colorectal cancer. Evid Based Complement Alternat Med. 2022;2022:1534083.
25. Goni O, Khan MF, Rahman MM, et al. Pharmacological insights on the antidepressant, anxiolytic, and aphrodisiac potentials of Aglaonema hookerianum Schott. J Ethnopharmacol. 2021;268:113664.
26. Vieira G, Cavalli J, Gonçalves ECD, et al. Antidepressant-like effect of Terpineol in an inflammatory model of depression: involvement of the cannabinoid system and D2 dopamine receptor. Biomolecules. 2020;10(5):792.
27. Akkol EK, Tatlı II, Karatoprak GŞ, et al. Is Emodin with anticancer effects completely innocent? Two sides of the coin. Cancers (Basel). 2021;13(11):2733.
28. Tabassum R, Vaibhav K, Shrivastava P, et al. Centella Asiatica attenuates the neurobehavioral, neurochemical, and histological changes in transient focal middle cerebral artery occlusion rats. Neurol Sci. 2013;34(6):925-933.
29. Chen SW, Wang WJ, Li WJ, et al. Anxiolytic-like effect of Asiaticonsider in mice. Pharmacol Biochem Behav. 2006;85(2):339-344.
30. Wang L, Guo T, Guo Y, Xu Y. Asiaticoside produces an antidepressant-like effect in a chronic unpredictable mild stress model of depression in mice, involving reversion of inflammation and the PKA/pCREB/BDNF signaling pathway. Mol Med Rep. 2020;22(3):2364-2372.
31. Li SQ, Xie YS, Meng QW, Zhang J, Zhang T. Neuroprotective properties of Madecassoside from Centella Asiatica after hypoxic-ischemic injury. Pak J Pharm Sci. 2016;29(6):2047-2051.
32. Sun T, Liu B, Li P. Nerve protective effect of Asiaticoside against ischemia-hypoxia in cultured rat cortex neurons. Med Sci Monit. 2015;21:3036-3041.
33. Hossain S, Hashimoto M, Katakura M, Al Mamun A, Shido O. Medicinal value of asiaticoside for Alzheimer's disease as assessed using single-molecule-detection fluorescence correlation spectroscopy, laser-scanning microscopy, transmission electron microscopy, and in silico docking. BMC Complement Altern Med. 2015;15:118.
34. Xu CL, Qu R, Zhang J, Li LF, Ma SP. Neuroprotective effects of madecassoside in the early stage of Parkinson's disease induced by MPTP in rats. Fitoterapia. 2013;90:112-118.
35. Wu F, Bian D, Xia Y, et al. Identification of major active ingredients responsible for burn wound healing of Centella asiatica herbs. Evid Based Complement Alternat Med. 2012;2012:848093.
36. Shen X, Guo M, Yu H, Liu D, Lu Z, Lu Y. Propionibacterium acnes related anti-inflammation and skin hydration activities of madecassoside, a pentacyclic triterpene saponin from Centella Asiatica. Biosci Biotechnol Biochem. 2019;83(3):561-568.
37. Byakodi M, Bagewadi Z, Muddapur U. Phytoconstituents profiling and evaluation of antimicrobial and antioxidant attributes of methanolic extract of Centella Asiatica. Res J Pharmaceut Biol Chem Sci. 2018;9(3):493-500.
38. Bhaumik SK, Paul J, Naskar K, Karmakar S, De T. Asiaticoside induces tumor-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony susceptible and -resistant Leishmania donovani strains. J Antimicrob Chemother. 2012;67(4):910-920.
39. Han AR, Lee S, Han S, et al. Triterpenoids from the leaves of Centella asiatica inhibit ionizing radiation-induced migration and invasion of human lung cancer cells. Evid Based Complement Alternat Med. 2020;2020:3683460.
40. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459-480.
41. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133-150.
42. Hanapi NA, Mohamad Arshad AS, Abdullah JM, Tengku Muhammad TS, Yusof SR. Blood-brain barrier permeability of Asiaticoside, Madecassoside, and Asiatic acid in porcine brain endothelial cell model. J Pharm Sci. 2021;110(2):698-706.
43. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2009;1788(4):842-857.
44. Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluid Barrier CNS. 2020;17(1):69.
45. Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 2007;16(3):285-299.
46. Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15(4):275-292.
47. Miao R, Xia LY, Chen HH, Huang HH, Liang Y. Improved classification of blood-brain-barrier drugs using deep learning. Sci Rep. 2019;9(1):8802.
48. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.
49. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412. doi:10.1101/cshperspect. a020412
50. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance, and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584-1596.
51. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541-5554.
52. Mantzavinos V, Alexiou A. Biomarkers for Alzheimer's disease diagnosis. Curr Alzheimer Res. 2017;14(11):1149-1154.
53. Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson's disease: recent advancement. Neurosci Bull. 2017;33(5):585-597.
54. Hou Y, Dan X, Babbar M, et al. Aging as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565-581.
55. Tarafdar A, Pula G. The role of NADPH oxidases and oxidative stress in neurodegenerative disorders. Int J Mol Sci. 2018;19(12):3824.
56. Kritsilis M, Rizou SV, Koutsoudaki PN, Evangelou K, Gorgoulis VG, Papadopoulos D. Ageing, cellular senescence, and neurodegenerative disease. Int J Mol Sci. 2018;19(10):2937.
57. Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell. 2019;18(6):e13031.
58. Tönnies E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer's disease. J Alzheimer's Dis. 2017;57(4):1105-1121.
59. Chen CL, Tsai WH, Chen CJ, Pan TM. Centella Asiatica extract protects against amyloid β1-40-induced neurotoxicity in neuronal cells by activating the antioxidative defense system. J Tradit Complement Med. 2015;6(4):362-369.
60. Haleagrahara N, Ponnusamy K. Neuroprotective effect of Centella asiatica extract (CAE) on experimentally induced parkinsonism in aged Sprague-Dawley rats. J Toxicol Sci. 2010;35(1):41-47.
61. Hafiz ZZ, Amin M, Johari James RM, Teh LK, Salleh MZ, Adenan MI. Inhibitory effects of raw-extract Centella Asiatica (RECA) on acetylcholinesterase, inflammations, and oxidative stress activities via in vitro and in vivo. Molecules. 2020;25(4):892.
62. Orhan IE, Atasu E, Senol FS, et al. Comparative studies on Turkish and Indian Centella asiatica (L.) urban (gotu kola) samples for their enzyme inhibitory and antioxidant effects and phytochemical characterization. Ind Crops Prod. 2013;47:316-322.
63. Xu CL, Wang QZ, Sun LM, et al. Asiaticoside: attenuation of neurotoxicity induced by MPTP in a rat model of parkinsonism via maintaining redox balance and up-regulating the ratio of Bcl-2/Bax. Pharmacol Biochem Behav. 2012;100(3):413-418.
64. Sampath U, Janardhanam VA. Asiaticoside, a trisaccharide triterpene induces biochemical and molecular variations in the brains of mice with Parkinsonism. Transl Neurodegeneration. 2013;2(1):23.
65. Stegner D, Klaus V, Nieswandt B. Platelets as modulators of cerebral ischemia/reperfusion injury. Front Immunol. 2019;10:2505.
66. Zhang C, Chen S, Zhang Z, et al. Asiaticoside alleviates cerebral ischemia-reperfusion injury via NOD2/mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-κB) signaling pathway. Med Sci Monit. 2020;26:e920325.
67. Luo Y, Wang C, Li WH, et al. Madecassoside protects BV2 microglial cells from oxygen-glucose deprivation/reperfusion-induced injury via inhibition of the toll-like receptor 4 signaling pathway. Brain Res. 2018;1679:144-154.
68. Zhou Y, Wang S, Zhao J, Fang P. Asiaticoside attenuates neonatal hypoxic-ischemic brain damage through inhibiting TLR4/ NF-κB/STAT3 pathway. Ann Translation Med. 2020;8(10):641.
69. Solstrand Dahlberg L, Becerra L, Borsook D, Linnman C. Brain changes after spinal cord injury, a quantitative meta-analysis, and review. Neurosci Biobehav Rev. 2018;90:272-293.
70. Fan L, Li X, Liu T. Asiaticoside inhibits neuronal apoptosis and promotes functional recovery after spinal cord injury in rats. J Mol Neurosci. 2020;70(12):1988-1996.
71. Luo Y, Fu C, Wang Z, Zhang Z, Wang H, Liu Y. Asiaticoside attenuates the effects of spinal cord injury through antioxidant and anti-inflammatory effects, and inhibition of the p38-MAPK mechanism. Mol Med Rep. 2015;12(6):8294-8300.
72. Maron E, Nutt D. Biological markers of generalized anxiety disorder. Dialogues Clin Neurosci. 2017;19(2):147-158.
73. Cuijpers P, Quero S, Dowrick C, Arroll B. Psychological treatment of depression in primary care: recent developments. Curr Psychiatry Rep. 2019;21(12):129.
74. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107.
75. Jana U, Sur TK, Maity LN, Debnath PK, Bhattacharyya D. A clinical study on the management of generalized anxiety disorder with Centella Asiatica. Nepal Med Coll J. 2010;12(1):8-11.
76. Wanasuntronwong A, Tantisira MH, Tantisira B, Watanabe H. Anxiolytic effects of standardized extract of Centella Asiatica (ECa 233) after chronic immobilization stress in mice. J Ethnopharmacol. 2012;143(2):579-585.
77. Le-Niculescu H, Roseberry K, Gill SS, et al. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2021;26(7):2776- 2804.
78. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34.
79. Jeon SW, Kim YK. The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. J Inflamm Res. 2018;11:179-192.
80. Tundis R, Loizzo MR, Bonesi M, Menichini F. Potential role of natural compounds against skin aging. Curr Med Chem. 2015;22(12):1515- 1538.
81. Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy. 2015;45(3):566-574.
82. Lee Y, Choi HK, N'deh K, et al. Inhibitory effect of Centella asiatica extract on DNCB-induced atopic dermatitis in HaCaT cells and BALB/c mice. Nutrients. 2020;12(2):411.
83. Wang Y, Li S, Li C. Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity. Med Sci Monit. 2019;25:1017-1023.
84. Ling Y, Gong Q, Xiong X, et al. Protective effect of madecassoside on H2O2-induced oxidative stress and autophagy activation in human melanocytes. Oncotarget. 2017;8(31):51066-51075.
85. Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Research. 2018;7:F1000 faculty Rev-1953.
86. Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol. 2002;138(11):1462-1470.
87. Haftek M, Mac-Mary S, Le Bitoux MA, et al. Clinical, biometric, and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skin. Exp Dermatol. 2008;17(11):946-952.
88. Sawant O, Khan T. Management of periorbital hyperpigmentation: An overview of nature-based agents and alternative approaches. Dermatol Ther. 2020;33(4):e13717.
89. Lee J, Jung E, Lee H, Seo Y, Koh J, Park D. Evaluation of the effects of a preparation containing asiaticoside on periocular wrinkles of human volunteers. Int J Cosmet Sci. 2008;30:167-173.
90. Jung E, Lee JA, Shin S, Roh KB, Kim JH, Park D. Madecassoside inhibits melanin synthesis by blocking ultraviolet-induced inflammation. Molecules. 2013;18(12):15724-15736.
91. Bylka W, Znajdek-Awiżeń P, Studzińska-Sroka E, Brzezińska M. Centella Asiatica in cosmetology. Postepy Dermatol Alergol. 2013;30(1):46-49.
92. Kongkaew C, Meesomperm P, Scholfield CN, Chaiwiang N, Waranuch N. Efficacy and safety of Centella Asiatica (L.) Urb. On wrinkles: a systematic review of published Data and network meta-analysis. J Cosmet Sci. 2020;71(6):439-454.
93. Mari W, Alsabri SG, Tabal N, Younes S, Sherif A, Simman R. Novel insights on understanding of keloid scar: article review. J Am Coll Clin Wound Special. 2016;7(1–3):1-7.
94. Singkhorn S, Tantisira MH, Tanasawet S, Hutamekalin P, Wongtawatchai T, Sukketsiri W. Induction of keratinocyte migration by ECa 233 is mediated through FAK/Akt, ERK, and p38 MAPK signaling. Phytother Res. 2018;32(7):1397-1403.
95. Unahabhokha T, Sucontphunt A, Nimmannit U, Chanvorachote P, Yongsanguanchai N, Pongrakhananon V. Molecular signalings in keloid disease and current therapeutic approaches from natural based compounds. Pharm Biol. 2015;53(3):457-463.
96. Song J, Xu H, Lu Q, et al. Madecassoside suppresses migration of fibroblasts from keloids: involvement of p38 kinase and PI3K signaling pathways. Burns. 2012;38(5):677-684.
97. Wu X, Bian D, Dou Y, et al. Asiaticoside hinders the invasive growth of keloid fibroblasts through inhibition of the GDF-9/MAPK/Smad pathway. J Biochem Mol Toxicol. 2017;31(8):e21922.
98. Lee J, Jung E, Kim Y, et al. Asiaticoside induces human collagen I synthesis through TGFbeta receptor I kinase (TbetaRI kinase)- independent Smad signaling. Planta Med. 2006;72(4):324-328.
99. Bahramsoltani R, Farzaei MH, Rahimi R. Medicinal plants and their natural components as future drugs for the treatment of burn wounds: an integrative review. Arch Dermatol Res. 2014;306(7):601-617.
100. Liu M, Dai Y, Li Y, et al. Madecassoside isolated from Centella asiatica herbs facilitates burn wound healing in mice. Planta Med. 2008;74(8):809-815.
101. Kimura Y, Sumiyoshi M, Samukawa K, Satake N, Sakanaka M. Facilitating action of asiaticoside at low doses on burn wound repair and its mechanism. Eur J Pharmacol. 2008;584(2–3):415-423.
102. Somboonwong J, Kankaisre M, Tantisira B, Tantisira MH. Wound healing activities of different extracts of Centella Asiatica in the incision and burn wound models: an experimental animal study. BMC Complement Altern Med. 2012;12:103.
103. Intararuchikul T, Teerapattarakan N, Rodsiri R, et al. Effects of Centella asiatica extract on antioxidant status and liver metabolome of rotenone-treated rats using GC-MS. Biomed Chromatogr. 2019;33(2):e4395.
104. Duggina P, Kalla CM, Varikasuvu SR, Bukke S, Tartte V. Protective effect of Centella triterpene saponins against cyclophosphamide-induced immune and hepatic system dysfunction in rats: its possible mechanisms of action. J Physiol Biochem. 2015;71(3):435-454.
105. Zhang L, Li HZ, Gong X, et al. Protective effects of Asiaticoside on acute liver injury induced by lipopolysaccharide/D-galactosamine in mice. Phytomedicine. 2010;17(10):811-819.
106. Wang W, Wu L, Li Q, et al. Madecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF- κB and activating Nrf2/HO-1 signaling. Biomed Pharmacother. 2018;103:1137-1145.
107. Park DW, Jeon H, Kwon JE, et al. Hepatoprotective effect of Centella Asiatica 50% ethanol extract against acetaminophen-induced acute liver injury in BALB/c mice. Toxicol Res. 2020;37(2):261-275.
108. Suresh K, Shimoda LA. Lung circulation. Comprehensive Phys Ther. 2016;6(2):897-943.
109. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914.
110. Wang XB, Wang W, Zhu XC, et al. The potential of asiaticoside for TGF-β1/Smad signaling inhibition in prevention and progression of hypoxia-induced pulmonary hypertension. Life Sci. 2015;137:56- 64.
111. Wang X, Cai X, Wang W, et al. Effect of asiaticoside on endothelial cells in hypoxia-induced pulmonary hypertension. Mol Med Rep. 2018;17(2):2893-2900.
112. Markopoulos GS, Roupakia E, Tokamani M, et al. Roles of NF-kappa B signaling in the regulation of miRNAs impacting on inflammation in cancer. Biomedicine. 2018;6(2):40.
113. Qiu J, Yu L, Zhang X, et al. Asiaticoside attenuates lipopolysaccharide-induced acute lung injury via down-regulation of the NF-κB signaling pathway. Int Immunopharmacol. 2015;26(1):181- 187.
114. Peng LY, Shi HT, Yuan M, et al. Madecassoside protects against LPS-induced acute lung injury via inhibiting TLR4/NF-κB activation and blood-air barrier permeability. Front Pharmacol. 2020;11:807.
115. Luo J, Zhang T, Zhu C, et al. Asiaticoside might attenuate bleomycin-induced pulmonary fibrosis by activating cAMP and Rap1 signaling pathways assisted by A2AR. J Cell Mol Med. 2020;24(14):8248-8261.
116. Lu GX, Bian DF, Ji Y, et al. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen deposition. Phytother Res. 2014;28(8):1224-1231.
117. Dang JW, Lei XP, Li QP, Dong WB. Asiaticoside attenuates hyperoxia-induced lung injury in vitro and in vivo. Iran J Basic Med Sci. 2019;22(7):797-805.
118. Panizo S, Martínez-Arias L, Alonso-Montes C, et al. Fibrosis in chronic kidney disease: pathogenesis and consequences. Int J Mol Sci. 2021;22(1):408.
119. Zhang M, Liu S, Fang L, Wang G, Yin L. Asiaticoside inhibits renal fibrosis development by regulating the miR-142-5p/ACTN4 axis. Biotechnol Appl Biochem. 2021;69:313-322.
120. Bose M, Almas S, Prabhakar S. Wnt signaling and podocyte dysfunction in diabetic nephropathy. J Investig Med. 2017;65(8):1093- 1101.
121. Wang Z, Liu J, Sun W. Effects of asiaticoside on levels of podocyte cytoskeletal proteins and renal slit diaphragm proteins in adriamycin-induced rat nephropathy. Life Sci. 2013;93(8):352-358.
122. Masola B, Oguntibeju OO, Oyenihi AB. Centella Asiatica ameliorates diabetes-induced stress in rat tissues via influences on antioxidants and inflammatory cytokines. Biomed Pharmacother. 2018;101:447-457.
123. Zhu Q, Zeng J, Li J, et al. Effects of compound Centella on oxidative stress and Keap1-Nrf2-ARE pathway expression in diabetic kidney disease rats. Evid Based Complement Alternat Med. 2020;2020:9817932.
124. Su Z, Ye J, Qin Z, Ding X. Protective effects of madecassoside against doxorubicin-induced nephrotoxicity in vivo and in vitro. Sci Rep. 2015;5:18314.
125. Razali N, Ng CT, Fong LY. Cardiovascular protective effects of Centella Asiatica and its triterpenes: a review. Planta Med. 2019;85(16):1203-1215.
126. Zhang J, Yao M, Jia X, Xie J, Wang Y. Hexokinase II upregulation contributes to Asiaticoside-induced protection of H9c2 Cardioblasts during oxygen-glucose deprivation/Reoxygenation. J Cardiovasc Pharmacol. 2020;75(1):84-90.
127. Bian GX, Li GG, Yang Y, et al. Madecassoside reduces ischemia-reperfusion injury on regional ischemia-induced heart infarction in rats. Biol Pharm Bull. 2008;31(3):458-463.
128. Wu K, Yao G, Shi X, et al. Asiaticoside ameliorates acinar cell necrosis in acute pancreatitis via the toll-like receptor 4 pathway. Mol Immunol. 2021;130:122-132.
129. Elhassan S, Candasamy M, Ching TS, Heng YK, Bhattamisra SK. Effect of madecassoside and catalpol in amelioration of insulin sensitivity in pancreatic (INS-1 E) β-cell line. Nat Prod Res. 2019;35:1-5.
130. Fong LY, Ng CT, Zakaria ZA, et al. Asiaticoside inhibits TNF-α- induced endothelial Hyperpermeability of human aortic endothelial cells. Phytother Res. 2015;29(10):1501-1508.
131. Zheng J, Zhang L, Wu M, Li X, Zhang L, Wan J. Protective effects of asiaticoside on sepsis-induced acute kidney injury in mice. China J Chin Mater Med. 2010;35(11):1482-1485.
132. Khameneh HJ, Ho AW, Laudisi F, et al. C5a regulates IL-1β production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis. Front Pharmacol. 2017;8:10.
133. Lu X, Zeng R, Lin J, et al. Pharmacological basis for use of madecassoside in gouty arthritis: anti-inflammatory, anti-hyperuricemic, and NLRP3 inhibition. Immunopharmacol Immunotoxicol. 2019;41(2):277-284.
134. Li H, Gong X, Zhang L, et al. Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice. Phytomedicine. 2009;16(6–7):538-546.
135. Yu WG, Shen Y, Wu JZ, Gao YB, Zhang LX. Madecassoside impedes invasion of rheumatoid fibroblast-like synoviocytes from adjuvant arthritis rats via inhibition of NF-κB-mediated matrix metalloproteinase-13 expression. Chin J Nat Med. 2018;16(5):330- 338.
136. Dou Y, Luo J, Yu J, Xia Y, Dai Y. Cholinergic system is involved in the therapeutic effect of madecassoside on collagen-induced arthritis in rats. Int Immunopharmacol. 2019;75:105813.
137. Wang T, Wei Z, Dou Y, et al. Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailability. Biochem Pharmacol. 2015;94(1):30-38.
138. Qiao S, Lian X, Yue M, et al. Regulation of gut microbiota substantially contributes to the induction of intestinal Treg cells and the consequent anti-arthritis effect of madecassoside. Int Immunopharmacol. 2020;89(Pt A):107047.
139. Funes SC, Rios M, Escobar-Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186-195.
140. Huang J, Zhou X, Shen Y, et al. Asiaticoside loading into polylactic-glycolic acid electrospun nanofibers attenuates host inflammatory response and promotes M2 macrophage polarization. J Biomed Mater Res A. 2020;108(1):69-80.
141. González-de-Olano D, Álvarez-Twose I. Mast cells as key players in allergy and inflammation. J Investig Allergol Clin Immunol. 2018;28(6):365-378.
142. Jiang JZ, Ye J, Jin GY, et al. Asiaticoside mitigates allergic inflammation by abrogating the degranulation of mast cells. J Agric Food Chem. 2017;65(37):8128-8135.
143. Wan J, Gong X, Jiang R, Zhang Z, Zhang L. Antipyretic and anti-inflammatory effects of asiaticoside in lipopolysaccharide-treated rat through up-regulation of heme oxygenase-1. Phytother Res. 2013;27(8):1136-1142.
144. Araujo JA, Zhang M, Yin F. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol. 2012;3:119.
145. Soyingbe OS, Mongalo NI, Makhafola TJ. In vitro antibacterial and cytotoxic activity of leaf extracts of Centella Asiatica (L.) Urb, Warburgia salutaris (Bertol. F.) Chiov and Curtisia dentata (Burm. F.) C.A.Sm - medicinal plants used in South Africa. BMC Complement Alternat Med. 2018;18(1):315.
146. Dash B, Faruquee H, Biswas S, Alam M, Sisir S, Prodhan UK. Antibacterial and antifungal activities of several extracts of Centella asiatica L. against some human pathogenic microbes. Life Sci Med Res. 2011:1-5.
147. Huang Q, Zhang S, Huang R, et al. Isolation and identification of an anti-hepatitis B virus compound from Hydrocotyle sibthorpioides lam. J Ethnopharmacol. 2013;150(2):568-575.
148. Monton C, Settharaksa S, Luprasong C, Songsak T. An optimization approach of dynamic maceration of Centella Asiatica to obtain the highest content of four centroids by response surface methodology. Rev Brasil Farmacogn. 2019;29(2):254-261.
149. Hiranvarachat B, Devahastin S, Soponronnarit S. Comparative evaluation of atmospheric and vacuum microwave-assisted extraction of bioactive compounds from fresh and dried Centella asiatica L. leaves. Int J Food Sci Technol. 2015;50:750-757.
150. Sen KK, Chouhan KBS, Tandey R, Mehta R, Mandal V. Impact of microwaves on the extraction yield of phenolics, flavonoids, and triterpenoids from Centella leaves: An approach toward digit botanical extraction. Pharmacogn Mag. 2019;15:S267-S273.
151. Rafamantanana MH, Rozet E, Raoelison GE, et al. An improved HPLC-UV method for the simultaneous quantification of triterpene glycosides and aglycones in leaves of Centella asiatica (L.) Urb (APIACEAE). J Chromatogr B. 2009;877(23):2396-2402. doi:10.1016/j.jchromb.2009.03.018
152. Shen Y, Liu A, Ye M, et al. Analysis of biologically active constituents in Centella Asiatica by microwave-assisted extraction combined with LC–MS. Chromatographia. 2009;70:431-438.
153. Randriamampionona D, Diallo B, Rakotoniriana F, et al. Comparative analysis of active constituents in Centella Asiatica samples from Madagascar: application for ex-situ conservation and clonal propagation. Fitoterapia. 2007;78(7–8):482-489.
154. Niamnuy C, Charoenchaitrakool M, Mayachiew P, Devahastin S. Bioactive compounds and bioactivities of Centella asiatica (L.) urban prepared by different drying methods and conditions. Dry Technol Int J. 2013;31:2007-2015.
155. Kim W-J, Kim J, Veriansyah B, et al. Extraction of bioactive components from Centella asiatica using subcritical water. J Supercrit Fluid. 2009;48(3):211-216.
【For more info: david.deng@wecistanche.com / WhatApp:86 13632399501】






